Abstract
The diagnosis of pancreatic carcinoma is still a problem in nuclar medicine (1), and an improved pancreas imaging agent is urgently needed. Currently, L-I75Se)-seleno-methionine (SM) is used as an agent for the detection of pancreatic carcinoma (2), with 99mTc sulfur colloid often injected in addition in order to permit the substraction of the interfering liver back-ground from SM (3). This imaging procedure results in rather large radiation doses to the patient, especially since the biological half-time of SM (70 days) is comparable with the physical half-life (120 days) of 75Se (4). Additionally, significant numbers of false-positives and false-negatives make routine diagnosis difficult (5).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
McAfee JG. In: Radiopharmaceuticals. The Society of Nuclear Medicine, Subramanian G, Rhodes BA, Cooper JF et al. (eds), New York, 3:14, 1975.
Blau M, Manske RF, J. nucl. Med. 2: 102, 1961.
Zurowski S, Graban WT, Jabukowski W, Eur. J. nucl. Med. 2: 273, 1977.
Lathrop KA, Johnston RE, Blau M, Rothschild EO, J. Nucl. Med. 13, suppl. 6: 7, 1972.
Quinn JL, III. In: Nuclear Medicine, Wagner HN, Jr, (ed), HP Publising Comp. New York, 153–160, 1975.
Hoyte RM, Lin SS, Christman DR, Atkins HL, Hauser W, Wolf AP, J. nucl. Med. 12: 280, 1971.
Atkins HL, Christman DR, Fowler JS, Hauser W, Hoyte RM, Klopper JF, Lin SS, Wolf AP, J. nucl. Med. 13: 713, 1972.
Lambrecht RM, Atkins H, Elias H, Fowler JS, Lin SS, Wolf AP, J. nucl. Med. 15: 863, 1974.
Vaalburg W, Beerling-van der Molen HD, Woldring MG, Nucl. Med. 14: 60, 1975.
Washburn LC, Wieland BW, Sun TT, Hayes RL, Butler TA, J. nucl. Med. 19: 77, 1978.
Kung HF, Gilani S, Blau M, J. nucl. Med. 19: 393, 1978.
Washburn LC, Sun TT, Byrd BL, Hayes RL, Butler TA, J. nucl. Med. 20: 857, 1979.
Comar D, Cartron JC, Mazière M, et al. Eur. J. nucl. Med. 1: 11, 1976.
Syrota A, Comar D, Cerf M, Plummer D, Mazière M, Kellershohn C, J. nucl. Med. 20: 778, 1979.
Buonocore E, Hübner KF, Radiology 133: 195, 1979.
Hübner KF, Andrews GA, Buonocore E, Hayes RL, Washburn LC, Collmann IR, Gibbs WD, J. nucl. Med. 20: 507, 1979.
Duhm B, Maul W, Medenwald H, Patzschke K, Wegner LA, Z. Naturforschg. 20b: 434, 1965.
Duhm B, Maul W, Medenwald H, Patzschke K, Wegner LA, Schlossmann K, Z. Naturforschg, 22b: 70, 1967.
Tisljar U, Kloster G, Ritzl F, Stöcklin G, J. nucl. Med, 20: 973, 1979.
Ritzl F, Kloster G, Coenen HH, Tisljar U, Stöcklin G, J. nucl. Med. 22: 87, 1981, (abstract).
Kloss G, Becker H, Niemann E, Leven M, Patent 21, 45, 282 (Fed. Rep. Germany) 1975.
Kloss G, Leven M, Eur. J. nucl. Med. 4: 179, 1979.
Petzold G, Coenen HH, J. Lab. comp. Radiopharm. 18:1319, 1981.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Martinus Nijhoff Publishers, The Hague
About this chapter
Cite this chapter
Kloster, G., Coenen, H.H., Szabo, Z., Ritzl, F., Stöcklin, G. (1982). Radiohalogenated L-α-Methyltyrosines as Potential Pancreas Imaging Agents for PECT and SPECT. In: Cox, P.H. (eds) Progress in Radiopharmacology 3. Developments in Nuclear Medicine, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-7669-6_12
Download citation
DOI: https://doi.org/10.1007/978-94-009-7669-6_12
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-7671-9
Online ISBN: 978-94-009-7669-6
eBook Packages: Springer Book Archive